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Background: Conventional chemotherapy and radiotherapy for the treatment of lymphoma have notable
drawbacks, and passive immunotherapy using a monoclonal antibody is restricted to CD20-positive B cell lymphoma.
Therefore, new treatment types are urgently required, especially for T cell lymphoma. One type of new antitumour
therapy is the use of active immunotherapeutic agents, such as agonists of the Toll-like receptors (TLRs), which facilitate
the induction of prolonged antitumour immune responses.
Methods: We have synthesised a novel TLR7 agonist called SZU-101 and investigated the systemic antitumour effect
on a murine model of T cell lymphoma in vivo.
Results: Here, we report that the intratumoural administration of SZU-101 enhanced the effectiveness of a conventionally
used chemotherapeutic agent, doxorubicin (DOX). SZU-101 administration improved tumour clearance in a murine model
of T cell lymphoma. The novel combination of intratumourally administered SZU-101 and DOX generated strong cytokine
production and enhanced the cytotoxic T lymphocyte response, leading to the eradication of both local and distant
tumours in tumour-bearing mice.
Conclusions: These findings suggested that combined active immunotherapy can be developed as a promising
treatment for T cell lymphoma, which may further improve the effectiveness of the current standard
cyclophosphamide, DOX, vincristine and prednisone (CHOP) therapy.
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Traditional treatments for lymphoma, such as chemo-
therapy and radiotherapy, have notable drawbacks, and
passive immunotherapy using a monoclonal antibody is
restricted to CD20-positive B cell lymphoma. In addition,
resistance to the treatment is also observed [1]. Therefore,
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unless otherwise stated.novel therapy is treatment with active immunotherapeutic
agents, such as agonists of the TOLL-like receptors
(TLRs), which facilitate the induction of prolonged
antitumour immune responses.
TLRs are expressed on a series of immune cells, such as
dendritic cells, macrophages, B cells, T cells and natural
killer cells, and they recognise specific pathogen-associated
molecular patterns (PAMPs). With the exception of TLR3,
most TLR signalling depends on myeloid differentiation
primary-response protein 88 (MYD88). The activation of
MYD88-dependent signalling results in the activation of
NF-κB, IFN regulatory factors (IRFs) and activator protein
1 (AP-1), leading to the release of proinflammatory cyto-
kines and stimulatory molecules for the activation ofis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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and adaptive immunity, TLR signalling regulates cytokine
production, T helper and effector cells as well as
suppressor cells, such as regulatory T cells (Tregs) and
myeloid-derived suppressor cells (MDSCs) [3-6].
Recent studies have focused on TLR7, 8 and 9, which
are localised intracellularly to the endosomal membranes.
TLR7 activation by ligands, such as viral RNA or synthetic
agonists, induces strong TH-1-biassed immune responses
and thus leads to a durable tumouricidal effect by support-
ing the activation of CD8+ T cells [7]. In addition to the
eradication of large primary tumours, the combined appli-
cation targeting TLR7, 8 and 9 also established long-term
antitumour immunity [6]. For the treatment of lymphoma,
Jonathan and colleagues established a phase II clinical
study in which a TLR9 agonist (1018 ISS) was used with
rituximab for follicular lymphoma [8]. Enhanced antitu-
mour efficacy was also found when radiotherapy was com-
bined with the TLR9 agonist CpG DNA 1826 or the TLR7
agonist R848 [9,10].
In this study, we introduced a novel TLR7 agonist called
SZU-101 and sought to investigate its immunogenicity
and antitumour effects. We hypothesised that locally or
systemically administered SZU-101 in combination with
conventional chemotherapeutic agents would induce sys-
temic antitumour immune responses. In addition, as one
of the conventionally used chemotherapeutic agents for
lymphoma, doxorubicin was selected for the combined
treatment. Here, we demonstrated that intratumourally
administered SZU-101 enhanced the therapeutic effective-
ness of doxorubicin (DOX) through the generation of a
systemic immune response. The combined application
induced the release of proinflammatory cytokines, facili-
tated the maturation of dendritic cells and activated B
cells and T cells, leading to the eradication of both pri-
mary and distant tumours in a murine lymphoma model.
This study provides evidence for the translation of the
combined active immunotherapy to early phase clinical
trials for the treatment of lymphoma.
Results
SZU-101 activated dendritic cells, B cells and T cells and
induced cytokine production but did not directly affect
tumour cells
In this study, we first investigated whether the synthe-
sised SZU-101 compound activated TLR7 signalling and
primed the immune response. We introduced a TLR7-
NF-kB reporter system expressed in HEK-293 cells
and treated the cells with different doses of SZU-101.
We found that the reporter was activated after a 4-h
treatment and consistently induced reporter activity
by 50-fold with higher doses of SZU-101 or up to 23-
fold with a low dose of 1 μM SZU-101. The inductions
with treatments of more than 5 μM SZU-101 werecomparable to those of 250 ng/ml of TNF-α, which
directly activates the NF-kB reporter system (Figure 1A).
As TLR7 was localised intracellularly to the endosomal
membranes, we also treated HEK-293 cells with FITC-
labelled SZU-101 and confirmed that SZU-101 could
be transported into the cytoplasm (Additional file 1:
Figure S1). The result indicated that SZU-101 was a
TLR7 agonist that directly activated TLR7 signalling.
To investigate the immune activation effect of SZU-101,
splenocytes from SZU-101-treated (3 mg/kg) mice were
analysed by flow cytometry. The results revealed that
SZU-101 significantly induced the expression of the
early activation marker CD69 in both CD3+ T cells and
CD19+ B cells (Figure 1B). We also found that SZU-101
stimulated CD11c + dendritic cells (DCs) to express the
maturation and activation marker CD80 along with the
earlier marker of the immune response, CD86 (Figure 1C).
Furthermore, the systemic induction of cytokines in the
serum was analysed using ELISA (Figure 1D). The results
indicated that after a 2-h treatment, SZU-101 induced the
production of TNF-α to approximately 400 pg/ml, IFN-γ
to approximately 150 pg/ml, IL-6 to 6,000 pg/ml and
IL-12 to approximately 600 pg/ml, all of which were
almost undetectable in the serum of PBS-treated control
mice. After a 4-h treatment, the concentration of TNF-α
decreased to basal levels, and the concentration of IL-6
also decreased by nearly 20-fold, while the concentrations
of TH1 cytokines IFN-γ and IL-12 increased by approxi-
mately 1-fold each.
To confirm the expression of TLR7 in EL4 mouse
lymphoma cells, an anti-TLR7 antibody was used to per-
form the Western blot detection, and murine lymphoma
cells TK-1 and A20 were introduced as controls. The
results indicated that EL4, TK-1 and A20 expressed
endogenous TLR7, which was not detectable in HEK-
293 negative controls (Figure 2A). An MTT assay was
also performed to examine whether SZU-101 had a
potential direct effect on tumour cells (Figure 2B). The
result revealed that SZU-101 did not directly affect the
growth of EL4 cells. The application of DOX significantly
reduced EL4 cell viability, while the combined application
with SZU-101 did not show a significant effect.
SZU-101 in combination with DOX improves survival in a
murine model of T cell lymphoma
Tumour-bearing mice were grouped into six treatment
groups. As shown in Figure 3A, DOX was intratumou-
rally administered, and SZU-101 was administered either
intratumourally or intraperitoneally. The combined admin-
istration was performed by injecting both SZU-101 and
DOX intratumourally or by injecting DOX intratumourally
and injecting SZU-101 intraperitoneally. As indicated in
Figure 3B, 8-week-old mice were implanted with EL4 cells,
and the treatments began on the day when the tumour
Figure 1 SZU-101-activated immune response through TLR7 signalling. (A) SZU-101 induced the activation of TLR7-NF-κB signalling. The
solid line indicates the relative inductions by SZU-101 or TNF-α (as positive control) in a HEK-BLUE TLR7-specific reporter system. The dotted line
indicates the inductions of SZU-101 or TNF-α in the non-reporter HEK-293 controls (**p < 0.01, one-way ANOVA). (B), (C). The expression of CD69,
CD86 and CD80 after SZU-101 stimulation. Splenocytes were collected after 2 or 4 h post SZU-101 treatment and analysed by flow cytometry
(**p < 0.01, one-way ANOVA). (D) The induction of systemic cytokines was analysed by ELISA assay. The serums were collected after 2, 4 or 24 h
post treatment. Each group in the experiment contained five mice.
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treatment, the mice were observed for drug effectiveness
and long-term survival.
The first deaths were observed in the control group and
DOX group on day 21 (Figure 3C). After a 60-day obser-
vation, mice treated with SZU-101 showed a substantial
increase in long-term survival (defined as mice surviving
greater than 60 days) compared with that of the control
or DOX groups. Local administration of SZU-101 incombination with DOX moderately improved survival over
other SZU-101 treatment groups (p < 0.01, log-rank test).
Locally administered SZU-101 in combination with DOX
led to a systemic antitumour effect
Tumour-bearing mice were implanted with two tumours
on their backs, one on the left side and one on the right
side. As depicted in Figure 3A, all intratumourally admin-
istered drugs were applied to the right-side tumours,
Figure 2 SZU-101 exhibited no direct effect on EL4 cells. (A) Endogenous TLR7 expression was confirmed in the murine lymphoma cell lines
TK-1, A20 and EL4. (B) An MTT assay was performed to investigate the direct effect of SZU-101 on EL4 cell growth. (−p > 0.05 compared with
control; **p < 0.01 compared with control; − −p > 0.05 compared with DOX; one-way ANOVA).
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evaluate the systemic effect of treatment. Tumour volumes
were measured as described above until tumours in any
group were undetectable by the naked eye.
All drug treatments showed a significant antitumour
effect on the right-side tumours compared with PBS
controls (Figure 4A1). The combined treatments (either
combined administration intratumourally (CoAd i.t.) orFigure 3 Treatment schedule and survival curve. (A) The left cartoon sh
group (listed in the right table). (B) The schematic diagram indicated the c
1 to day 5, and DOX was administered on days 1, 3 and 5. (C) The survival
mice with different treatments. Each treatment group in the experiment coCoAd intraperitoneally (i.p.)) exhibited improved tumouri-
cidal effectiveness compared with single-drug treatments
(SZU-101 i.t., SZU-101 i.p. or DOX), after which the
tumours began to re-grow on day 11 (Figure 4A2). No
significant difference was observed between the CoAd i.t.
group and CoAd i.p. group (Figure 4A3).
On the left-side tumour, DOX treatment showed a mod-
erate suppressive effect compared with PBS treatmentows the administration methods of the drugs in each treatment
ourse schedule, in which the SZU-101 was administered daily from day
curve indicates 60-day survival post treatment of the tumour-bearing
ntained at least nine mice.
Figure 4 Therapeutic effectiveness of combined treatment. (A1–3). The antitumour effect of different treatments on the directly treated
right tumours. In (A2), the PBS control was excluded, and in (A3), only the combined treatments were compared. ((A1), *p < 0.05 compared
with PBS control; (A2), *p < 0.05 compared with combined treatments; one-way ANOVA) (B1–3) The antitumour effect of different treatments on
the untreated left tumours. In (B2), the PBS control was excluded, and in (B3), only the combined treatments were compared. ((B1), *p < 0.05
compared with PBS control; (B2), *p < 0.05 compared with SZU-101 treatments; (B3), *p < 0.05 compared with CoAd i.t.; one-way ANOVA). Each
treatment group contained at least nine mice.
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group grew substantially larger than those in other
treatment groups (SZU-101 i.t., SZU-101 i.p., CoAd i.t. or
CoAd i.p.), especially after day 9 (Figure 4B2). Compared
with the tumours in the CoAd i.p. group, the tumours
in the CoAd i.t. group were significantly suppressed,
and on day 15, the tumours were undetectable by the
naked eye. Meanwhile, we also observed that the
tumours in the CoAd i.p. group began to re-grow after
day 9 (Figure 4B3).
Long-term surviving mice generated an enhanced
immune response to tumour cells
After 60 days of observation for long-term survival, sur-
viving mice in the SZU-101 i.t., SZU-101 i.p., CoAd i.t.and CoAd i.p. treatment groups and normal untreated
mice were sacrificed, and lymphocytes from each mouse
were collected as effector cells. The effector cells were
subsequently co-cultured with EL4 mouse T cell lymph-
oma cells at an effector:target cells ratio of 10:1.
After a 24-h co-culture, the medium was collected and
centrifuged to remove the insoluble components. The
supernatant was subsequently assayed for cytokine produc-
tion by ELISA. The results indicated that the lymphocytes
collected from CoAd i.t.-treated surviving mice generated a
higher level of IFN-γ, which was approximately tenfold
compared with control and two- to threefold compared
with that from the SZU-101 i.t., SZU-101 i.p. or CoAd i.t.
groups. Furthermore, IL-6 production was only observed
from groups of intratumourally administered SZU-101,
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from the CoAd i.t. group compared with that from the
SZU-101 i.t. group.
Moreover, co-cultured cells were also utilised to assess
the cytotoxic T lymphocyte (CTL)-mediated cytotoxicity.
The results indicated that effector cells from the CoAd i.t.
group were significantly sensitive to EL4 tumour cells,
while the effector cells from the SZU-101 i.t., SZU-101 i.p.
and CoAd i.p. groups exhibited no intragroup significance
(Figure 5B). The cytotoxicity to EL4 tumour cells in the
control group was as low, as expected.
Discussion
Lymphoma is a type of malignant cancer in the lympho-
hematopoietic system, presenting as a solid tumour in
lymph nodes, which is called nodal lymphoma, or as
extranodal lymphoma in the lymphoid tissues of many
organs, such as the spleen, bone marrow, skin, brain,
liver and bowels. Recent studies have revealed that
combined immunotherapy for lymphoma may help
overcome the suppressive micro-environment, induce
tumour-specific immune response and improve tumour
clearance.
It was reported that the administration of a conventional
chemotherapeutic agent, such as cyclophosphamide or
DOX, in combination with TNF-α, enhanced the antitu-
mour effects against large established tumours in a murine
lymphoma model [11,12]. The standard cyclophospha-
mide, DOX, vincristine and prednisone (CHOP) therapy
was also used in combination with a monoclonal antibody,
rituximab (R-CHOP), for CD20-positive B cell lymphoma,
or with bryostatin 1 for human diffuse large cell lymph-
oma [13,14]. On the other hand, for immunotherapy,Figure 5 The immune response by co-culture of murine lymphocytes
were co-cultured with EL4 cells at an effector: target ratio of 10:1. (A) The c
compared with control; **p < 0.05 compared with other SZU-101 treatmen
(B) CTL-mediated cytotoxicity was assayed using the lymphocytes from mi
**p < 0.05 compared with other SZU-101 treatments; one-way ANOVA). Eacconventional antitumour therapy, such as monoclonal
antibodies, chemotherapeutic agents and radiotherapy,
was applied in combination with TLR agonists, such as
TLR9 agonist 1018 ISS, TLR9 agonist CpG DNA 1826
and TLR7 agonist R848 [8-10]. These findings suggested
that combined therapy with conventional drugs at a care-
fully selected dose and course schedule could lead to ad-
vanced antitumour effectiveness in lymphoma treatment.
In this study, we focused on establishing a therapeutic
schedule with the proper dose for the treatment of lymph-
oma using a TLR7 agonist synthesised in our lab com-
bined with chemotherapeutic drugs in a murine T cell
lymphoma model.
As the TLR7 was localised intracellularly, we intro-
duced a fluorescence imaging technique and found that
the synthesised compound can be transported to the
cytoplasm (Additional file 2: Figure S2). We also demon-
strated that SZU-101 can activate TLR7-NF-kB signal-
ling in a TLR7-specific system at a low concentration of
1 μM after 6 h of stimulation or at a higher concentra-
tion of 5 μM after 4 h of stimulation. These findings
suggested that SZU-101 is a TLR7 agonist and can in-
duce downstream signalling through TLR7 activation.
It was reported that TLR7 activation could lead to
strong TH-1-biassed immune responses and induce the
release of proinflammatory cytokines [7,15,16]. In our
study, we observed a high level of proinflammatory cyto-
kines, such as TNF-α, IFN-γ and IL-12 in sera from
SZU-101-treated tumour-bearing mice, while no induc-
tion of TH-2 cytokines IL-4, IL-5 or IL-10 was detected
(Figure 1D). We also observed that one TH-2-biassed
cytokine, IL-6 was significantly induced after agonism,
which was in line with others’ reports that the activationwith tumour cells. The lymphocytes from long-term surviving mice
ytokine induction of IFN-γ or IL-6 (IFN-γ production, ++p < 0.05
ts; IL-6, **p < 0.05 compared with SZU-101 i.t.; one-way ANOVA).
ce with different treatments (+p < 0.05 compared with control;
h group in the experiment contained at least six mice.
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of the cytokines observed above through the TLR7-
MYD88 pathway [17,10,18]. The TH-1 cytokines IFN-γ
and IL-12 were significantly induced after 4-h treatment.
However, more importantly, all induced cytokine produc-
tions were reduced to the basal level after 24-h treatment,
providing a critical clue for planning the treatment sched-
ule. Furthermore, TLR7 agonists could also significantly
up-regulate the activation marker CD69 on B/T cells and
activate dendritic cells [16,10]. In the study, we also found
that the application of SZU-101 significantly induced the
expression of the activation marker CD69 on B/T cells
and stimulated the activation of dendritic cells (Figure 1C).
These findings indicated that SZU-101 is a functional
TLR7 agonist that can induce a strong immune response
in tumour-bearing mice with such high effectiveness that
the effect of SZU-101 on cytokine release and activation
of immune cells was observed as early as 2 h after
treatment.
In human lymphoma, the expression of TLR7 has been
demonstrated in several studies. TLR7 was widely expressed
in human follicular lymphoma (FL), diffuse large B cell
lymphoma (DBCL) and peripheral T cell lymphoma (PTCL)
as well as in other lymphocytic diseases, such as chronic
lymphocytic leukaemia (CLL) [19-21]. In this study, as
most of the murine lymphoma cells expressed endogen-
ous TLR7 (Figure 2A), we sought to investigate whether
SZU-101 had a direct effect on the tumour cells. The
MTT assay results indicated that SZU-101 had no direct
effect on EL4 tumour cells (Figure 2B), which was in line
with others’ findings of another TLR7 agonist, imiquimod,
on acute myeloid leukaemia (AML) cells, whereas the
TLR7/8 agonist R848 may lead to terminal differentiation
and suppressed cell proliferation in AML [22].
For lymphoma treatment, the low immunogenicity and
immunosuppression have been the most problematic issues
in the development of anticancer therapies. As described
above, the combined application of conventional antitu-
mour therapies with immune stimuli may provide potential
strategies for lymphoma treatment. For instance, for B cell
lymphoma, the TLR1/2 agonist (Pam3CSK4) was applied
with the conventional chemotherapeutic agent Ara-C,
resulting in a synergistic anticancer effect through the
up-regulation of immunomodulatory molecules [23].
In our murine model of T cell lymphoma, the applica-
tion of a conventional chemotherapeutic agent, DOX,
which is a component of CHOP therapy, in combination
with TLR7 agonist SZU-101, significantly improved sur-
vival compared with PBS treatment or DOX treatment
alone. However, based on the survival data, no significance
difference was observed between SZU-101-treated groups
within 60 days post treatment (log-rank test, Figure 3C).
As the anticancer immunotherapy of TLR agonists
could lead to the quick release and systemic dispersionof proinflammatory cytokines, the dose and administra-
tion method must be carefully selected [24]. To determine
the treatment schedule and administration method, we
chose a relatively low dose of DOX (3 mg/kg) and applied
DOX every 2 days, such that the total usage of DOX was
approximately 50% less than a previous study on CHOP
therapy in a murine model of lymphoma [14]. Regarding
the administration method, it was reported that the local
administration of the TLR7 agonist imiquimod with anti-
CD40 immunotherapy exhibited a strong antitumour effect
in a murine model of malignant mesothelioma [25]. How-
ever, others have reported that the systemic administration
of R848 with radiotherapy primed durable antitumour
immune responses in a murine model of lymphoma [10].
In this study, we sought to include both local and systemic
administration of SZU-101 to investigate the proper ad-
ministration method for the combined therapy.
We generated a murine tumour model, in which two
tumours were implanted on the same mouse to assess
the local and systemic antitumour effect of the treat-
ments. On the local tumour, which was directly treated
with the drugs, the combined therapy led to significant
improvement of the tumouricidal effect, especially 1 week
post treatment, whereas the tumours in other groups
began to re-grow (Figure 4A). However, in the distant
tumour, which was not directly treated, DOX showed
relatively low effectiveness compared with other treatments.
We also observed that only DOX in combination with
intratumourally administered SZU-101 (as local administra-
tion) exhibited a durable antitumour effect on the distant
tumours, while tumour re-growth was noted in other
groups of treatments, including the treatment of DOX in
combination with intraperitoneally administered SZU-101
(as systemic administration; Figure 4B). These findings
suggested that combined therapy with DOX and SZU-101
by local administration exhibited the best therapeutic per-
formance in the murine model of EL4 T cell lymphoma by
generating a strong local antitumour effect and inducing a
systemic immune response against a distant tumour.
As the major effect of the activation of TLR7 is the
induction of IFN-γ [18], we observed that when EL4
tumour cells were co-cultured with lymphocytes from
the surviving mice treated by SZU-101, especially with
the lymphocytes from the CoAd i.t. group, IFN-γ release
was significantly increased (Figure 5A). We also found
increased IL-6 induction when EL4 cells were co-cultured
with lymphocytes from intratumourally administered
SZU-101-treated mice (Figure 5A), suggesting that the
intratumourally administered SZU-101 may have triggered
an IL-6-based tumour-specific memory immune response.
Furthermore, it was reported that the activation of TLR1/
TLR2 signalling by a synthetic bacterial lipoprotein ex-
hibits potential antitumour capabilities of up-regulating
CTL function [26]. In this study, we found a similar result
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lymphocytes from SZU-101-treated surviving mice was
significantly increased. In fact, lymphocytes from the
CoAd i.t. group exhibited a 200% enhancement in CTL
function (Figure 5B). Although the underlying mecha-
nisms of the enhanced antitumour immune response by
this combined therapy are unclear, based on the current
data, we speculate that intratumourally administered
SZU-101 enhances the process of antigen presentation
on the tumour site where the tumour-specific antigens
were concentrated by DOX-induced tumour cell death,
while simultaneously activating immune cells to generate
a durable systemic antitumour effect.Conclusions
In this study, we demonstrated for the first time that
intratumourally administered TLR7 agonist SZU-101 can
enhance the antitumour effectiveness of a conventionally
used chemotherapeutic agent, DOX. The novel combin-
ation of intratumourally administered SZU-101 and DOX
generated strong production of proinflammatory cytokines
and enhanced the CTL response, leading to the eradica-
tion of both local and distant tumours in the murine
model of T cell lymphoma. The important contribution
made in this study was the demonstration of the success-
fully selected dose and course schedule, which may lower
the side effects of chemotherapeutic drugs. We cannot
omit the fact that the intratumoural administration of
drugs to non-cutaneous tumours is often challenging, but
our research still suggested that this combined immuno-
therapy can be developed as a promising treatment for
lymphoma, which may further improve the effectiveness
of the current standard CHOP therapy.Methods
Mice, cell lines and animal model
The C57BL/6 mice used in this study were purchased
from Guangdong Medical Laboratory Animal Center
(Guangdong, China). The EL4 T cell lymphoma cells were
maintained in DMEM (Gibco) with 10% FBS and 100 U/ml
penicillin-streptomycin.Table 1 Dose of SZU-101 and DOX in drug treatments
Group Final con. and dose of SZU-101 Final con. and do
Ctrl - -
DOX - 1.6 μg/μl; 4 mg/kg
SZU-101 i.t. 1.2 μg/μl; 3 mg/kg -
SZU-101 i.p. 0.6 μg/μl; 3 mg/kg -
CoAd i.t. 1.2 μg/μl; 3 mg/kg 1.6 μg/μl; 4 mg/kg
CoAd i.p. 0.6 μg/μl; 3 mg/kg 1.6 μg/μl; 4 mg/kg
The combined administration was performed by injecting SZU-101 and DOX intratu
intraperitoneally (CoAd i.p.).The C57BL/6 mouse lymphoma model was developed
through the subcutaneous implantation of EL4 cells.
Briefly, 1 × 106 EL4 cells were inoculated subcutane-
ously on day 0 of each experiment. The mice were
ready for experiments on day 7, when the tumours were
approximately 500–1,000 mm3; the tumour volume was
calculated using the following equation: [tumour vol-
ume = short axis2 × long axis/2] [27]. A visible tumour
size of 20 mm in diameter was defined as the endpoint
criterion, and those mice that met the criterion were
sacrificed according to the AVMA guidelines on
euthanasia.
All animal experiments were performed with the
approval of Laboratory Animal Welfare and Ethics
Committee, School of Medicine, Shenzhen University.Western blotting
The anti-TLR7 antibody was purchased from Santa Cruz
Biotechnology and was applied to confirm TLR7 expres-
sion in the mouse lymphoma cell lines EL4, TK-1 and
A20. Cell lysates were subjected to electrophoresis using
10% SDS-PAGE gels and transferred to PVDF membranes.
The membranes were incubated with primary and second-
ary antibodies with proper blocking procedures and finally
exposed to X-ray film (Fuji).HEK-BLUE assay
The TLR7 agonist SZU-101 was synthesised as described
in Additional file 2: Figure S2. HEK-BLUE hTLR7 cells
were purchased from InvivoGen. The cells stably expressed
human TLR7 and a SEAP reporter, which can be used to
detect TLR7 agonism through the activation of NF-kB
signalling. The cells were maintained in selective DMEM
growth medium with an additional 10 μg/ml blasticidin
and 100 μg/ml Zeocin™. After incubation with different
doses of SZU-101, the cells were tested using the HEK-
BLUE detection kit according to the manufacturer’s
instructions. The TLR7 agonist imiquimod and purified
mouse TNF-α were used as positive controls. The induc-
tion of TLR7 activation can be visualised and assessed by
reading the OD at 620–655 nm.se of DOX Injection i.t. (drug/PBS) Injection i.p. (drug/PBS)
-/50 μl -/100 μl
50 μl/- -/100 μl
50 μl/- -/100 μl
-/50 μl 100 μl/-
50 μl/- -/100 μl
50 μl/- 100 μl/-
mourally (CoAd i.t.) or injecting DOX intratumourally, while injecting SZU-101
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A CellTiter® 96 MTS assay (Promega) was performed ac-
cording to the manufacturer’s instructions. Briefly, 1 × 104
EL4 cells were seeded in each well with PBS, SZU-101
(3 μg/μl), DOX (2 μg/μl) or SZU-101 combined with
DOX. Cell viability was evaluated after a 24-h incubation.
Flow cytometry
On day 7, the tumour-bearing mice were treated with
3 mg/kg SZU-101 or 4 mg/kg DOX by intraperitoneal
administration. Mouse spleens were collected at 2, 4 or
24 h post treatment on day 8, and the splenocytes were
prepared by removing the red blood cells with RBC lysis
buffer (BioLegend) after separating the cells through a
70-μm cell strainer. Approximately 1 × 106 cells were
stained with corresponding florescence antibodies and
analysed by FACSCalibur flow cytometry (BD Biosciences).
The antibodies for flow cytometry were purchased from
BioLegend and included the following: anti-CD11c-
Alexa488, anti-CD86-PerCP/Cy5.5, anti-CD80-Alexa647,
anti-CD3-Alexa488, anti-CD19-Alexa647 and anti-CD69-
PerCP/Cy5.5.
ELISA
The tumour-bearing mice were intraperitoneally admin-
istered SZU-101 (3 mg/kg) or DOX (4 mg/kg) on day 7.
Sera samples were collected at 2, 4 or 24 h post treatment
on day 8 and stored at −20°C. An ELISA for multiple
cytokines in peripheral blood was performed using a
Ready-SET-Go!® ELISA kit (eBioscience) according to
the manufacturer’s instructions.
Drug administration and treatment schedule
EL4 lymphoma cells were inoculated subcutaneously at
two sites on the back of each mouse (approximately 20 g
in weight) on the left and right side. The SZU-101 stock
was prepared in DMSO at a concentration of 60 μg/μl,
and DOX was prepared in PBS at a concentration of
2 μg/μl. The drugs for the mice in each group were
prepared as described in Table 1.
DOX was applied on days 1, 4 and 7 of each course of
treatment, and SZU-101 was applied every 24 h. A total
of seven applications of SZU-101 and three applications
of DOX were applied for one course. Tumour growth was
measured daily, and long-term survival was evaluated.
Cytotoxicity assay
Tumour-bearing mice treated with different drugs or
combinations were sacrificed, and lymphocytes from each
mouse were collected. The effector cells were incubated
with EL4 mouse T cell lymphoma cells at an effector:target
cell ratio of 10:1. The cytotoxicity experiment was per-
formed using the CytoTox 96® Non-Radioactive Cytotox-
icity Assay Kit according to the manufacturer’s instructions.Statistical analysis
Each group of assay included at least five samples for
in vitro assays or ten mice for in vivo assays (except one
mouse died in SZU-101 i.t. group). Statistical analysis was
performed using SPSS 16 (IBM) and data was shown as
mean ± standard error of the mean (SEM). Data was
analysed by one-way ANOVA and a value of p < 0.05 was
considered statistically significant.
Additional files
Additional file 1: Figure S1. Fluorescein isothiocyanate (FITC) was
purchased from AMRESCO and was conjugated to SZU-101. The HEK-293 cells
were treated with unconjugated FITC or FITC-labelled SZU-101. The cells were
incubated for 30 min at 37°C protected from light. The cells were washed
twice with PBS and subsequently visualised by fluorescence microscopy.
Additional file 2: Figure S2. A. The schematic diagram indicated the
synthesis method for SZU-101. Compound 1 was synthesised according
to Wu’s methods [24] and was subsequently hydrogenated with R-Ni as
catalyst, under 1 atm hydrogen and room temperature for 12 h. The
filtered reaction mixture was concentrated by vacuum concentrator and
purified by silica chromatography. The structure of Compound 2 was
confirmed by 1H NMR and 13C NMR (B, C). Compound 2 was dissolved
in CH2Cl2 and mixed with one equivalent mole of succinic anhydride.
The mixture was stirred at RT for 12 h and heated at 60°C for 1 h. The
reaction mixture was cooled to room temperature and concentrated. The
concentrated residue was dissolved in 10% HCl and stirred overnight at
room temperature to obtain compound SZU-101. The structure of SZU-101
was confirmed by 1H NMR and 13C NMR (D, E).
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